PAGE 1 OF 3 PAGES

Amendment No. 7

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Heart and Vascular Clinic				In accordance with letter dated April 03, 2018.		4.	4. Expiration Date: January 31, 2020			
2. 620 Stanton Christiana Road, Suite 203 Newark, DE 19713			YJC,	License number: 07-31394-01 is amended in its entirety to read as follows:		01 is	5. Docket No.: 030-38183 Reference No.:			
6.	Byproduct, source, and/or special nuclear material	7.	Chemic	al and/or p	physical fo	orm 8.	Maximum amoun may possess at a under this license	ny one time	9.	Authorized use
A.	Any byproduct material permitted by 10 CFR 35.100	A.	Any	0.5		A.	As Needed	SIW	Α.	For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B.	Any byproduct material permitted by 10 CFR 35.200	B.	Any	T	IN	all all	As Needed	Ols	B.	For use in imaging and localization studies permitted by 10 CFR 35.200.

- 10. Licensed material may be used or stored at the licensee's facilities located at:
 - A. 620 Stanton Christiana Road, Suite 203, Newark, Delaware
 - B. 410 Foulk Road, Suite 101, Wilmington, Delaware
 - C. 212 Carter Dr., Suite D, Middletown, Delaware, 19709

NRC FORM 37	74A	U.S. NUCLEAR REGULA	TORY COMMISSION PAGE 2 OF 3 PAGES
	MATERIALS LICENSE	License Number 07-31394-01	Docket or Reference Number 030-38183
	JPPLEMENTARY SHEET	Amendment No. 7	
11. The F	Radiation Safety Officer (RSO) fo	or this license is Ashish D. Parikh,	M.D.
12. Licen	sed material shall only be used	by, or under the supply sion of: E	GULA
A. Ir	ndividuals permitted to work as a	authorized sers as appropriate in	accordance with 10 CFR 35.13 and 10 CFR 35.14.
B. T	he following individuals are auth	orized users for the material and	medical uses as indicated:
A	authorized Users	Material and Use	C
A	Ashish D. Parikh, M.D.	10 CFR 35 100,10 CFR 35	5.200
		Item 8, the licensee shall further in .35(d) for establishing decommiss	estrict the possession of licensed material to quantities below the
111311111	num imit specified in 10 CFR 30		
		STIN CONTRACTOR	
		4	3 78 3
		V	No
		BAA	A A Moles
		W W	

NRC FORM 374A	U.S. NUCLEAR REGUL	PAGE 3 OF 3 PAGES	
	License Number	Docket or Reference Number	
	07 04004 04		

MAT	ERIA	LS L	ICE	NSE
SUPPI	LEME	NTA	RY S	SHEET

07-31394-01

030-38183

Amendment No. 7

- 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents; including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated November 12, 2009 [ML093210357]
 - B. Letter dated October 26, 2016 [ML16326A043]
 - C. Letter dated April 3, 2018 [ML18103A184]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 18, 2018

Shawn Seelev

Region 1